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Abstract
Introduction The epidemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been 
spreading globally, raising increasing concerns. There are several controversial hypotheses on the potentially harmful or ben-
eficial effects of antihypertensive drugs acting on the renin–angiotensin–aldosterone system (RAAS) in coronavirus disease 
2019 (COVID-19). Furthermore, there is accumulating evidence, based on several observational studies, that angiotensin-
converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) do not increase the risk of contracting 
SARS-CoV-2 infection. On the other hand, conflicting findings regarding the role of ACEIs/ARBs as prognosis modifiers 
in COVID-19 hospitalised patients have been reported.
Objective The aim of this large-scale, retrospective cohort study was to investigate whether prior exposure to ACEIs and/or 
ARBs was associated with all-cause mortality among over 40,000 hospitalised COVID-19 patients compared with calcium 
channel blockers (CCBs), a potential therapeutic alternative.
Methods This study was conducted using COVID-19 registries linked to claims databases from Lombardy, Veneto and 
Reggio Emilia (overall, 25% of Italian population). Overall, 42,926 patients hospitalised between 21 February and 21 April 
2020 with a diagnosis of COVID-19 confirmed by real-time polymerase chain reaction tests were included in this study. 
All-cause mortality occurring in or out of hospital, as reported in the COVID-19 registry, was estimated. Using Cox models, 
adjusted hazard ratios (HRs) of all-cause mortality (along with 95% confidence intervals [CIs]) were estimated separately 
for ACEIs/ARBs and other antihypertensives versus CCBs and non-use.
Results Overall, 11,205 in- and out-of-hospital deaths occurred over a median of 24 days of follow-up after hospital admis-
sion due to COVID-19. Compared with CCBs, adjusted analyses showed no difference in the risk of death among ACEI (HR 
0.97, 95% CI 0.89–1.06) or ARB (HR 0.98, 95% CI 0.89–1.06) users. When non-use of antihypertensives was considered as 
a comparator, a modest statistically significant increase in mortality risk was observed for any antihypertensive use. How-
ever, when restricting to drugs with antihypertensive indications only, these marginal increases disappeared. Sensitivity and 
subgroup analyses confirmed our main findings.
Conclusions ACEI/ARB use is not associated with either an increased or decreased risk of all-cause mortality, compared 
with CCB use, in the largest cohort of hospitalised COVID-19 patients exposed to these drugs studied to date. The use of 
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these drugs therefore does not affect the prognosis of COVID-19. This finding strengthens recommendations of international 
regulatory agencies about not withdrawing/switching ACEI/ARB treatments to modify COVID-19 prognosis.
Key Points 
There is conflicting preclinical evidence on whether 
angiotensin-converting enzyme inhibitors (ACEIs) or 
angiotensin receptor blockers (ARBs) increase suscepti-
bility to severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) infection, although both hypotheses are 
biologically plausible.
There is also conflicting evidence on whether the use 
of ACEI/ARBs affects the prognosis of hospitalised 
patients with coronavirus disease 2019 (COVID-19).
This study found no difference in the risk of mortality 
associated with prior exposure to ACEIs or ARBs com-
pared with calcium channel blockers.
Prior use of ACEIs or ARBs does not modify prognosis 
in COVID-19 hospitalised patients.
1 Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) is responsible for the global coronavirus disease 
2019 (COVID-19) pandemic that has led to more than 11 
million infected patients and almost 540,000 deaths world-
wide as at 7 July 2020 [1]. Italy has been facing one of the 
largest outbreaks, with around 34,869 deaths currently [2].
There are several controversial hypotheses on the poten-
tially harmful or beneficial effects of antihypertensive drugs 
acting on the renin–angiotensin–aldosterone system (RAAS) 
in COVID-19 [3–5]. These hypotheses are based on the fact 
that angiotensin-converting enzyme 2 (ACE2) is the receptor 
binding site for SARS-CoV-2 in the target cell [6]. In vitro 
and in vivo studies have demonstrated that ACE inhibitors 
(ACEIs), as well as angiotensin-II receptor blockers (ARBs), 
can significantly increase ACE2 expression, thereby facili-
tating SARS-CoV-2 entry into cells [7, 8]. Mechanistically, 
it is possible that ACE2 tissue level changes in response to 
ACEIs/ARBs in humans, but large clinical studies have not 
yet confirmed this. However, it has also been found that viral 
binding to ACE2 decreases its surface expression and prevents 
angiotensin-II cleavage by ACE to generate angiotensin 1–7, 
which counterbalances the effect of angiotensin-II signalling 
through angiotensin receptor type-1 (AT1R). Hence, binding 
of angiotensin-II to AT1R leads to increased pulmonary vas-
cular permeability, resulting in lung injury [9, 10]. By blocking 
AT1R-mediated angiotensin-II adverse effects and increasing 
ACE2-mediated production of angiotensin 1–7 production, 
ARBs may counteract this effect and reduce lung damage [3].
Based on several observational studies (Online Resource 
1), there is accumulating evidence that ACEIs and ARBs do 
not increase the risk of contracting SARS-CoV-2 infection [11, 
12]. On the other hand, conflicting findings regarding the role 
of ACEIs/ARBs as prognosis modifiers in COVID-19 hospi-
talised patients have been reported. Published studies on this 
research question suffer from small sample size and potential 
residual confounding as they recruited small cohorts of hospi-
talised patients. Small sample sizes also do not permit sensitiv-
ity analyses to be conducted, including dose–effect analyses, 
which can corroborate the main findings [13–17]. Further-
more, the identification of all covariates related to prior use of 
chronic medications, as well as comorbidities and a history of 
prior hospitalisations, may not be accurately evaluated in this 
setting during a healthcare emergency if data are collected pro-
spectively. The mixed quality of studies investigating whether 
ACEI/ARB use modifies the prognosis of COVID-19 is seen 
by the fact that two meta-analyses of observational studies 
reported contrasting results. One meta-analysis suggested a 
protective effect of RAAS inhibitors regarding all-cause mor-
tality and critical illness [18], while the other found no signifi-
cant association with all-cause mortality [19]. In addition to 
the contradictory results, these meta-analyses are problematic 
because they included an observational study that has since 
been retracted [20]. This highlights the need for a large-scale 
study using appropriate methods to investigate whether prior 
ACEI/ARB use among persons with COVID-19 improves or 
worsens the prognosis of persons infected with SARS-CoV-2. 
Ascertaining the impact of these drugs is essential because 
it has been suggested that withdrawing RAAS inhibitors and 
switching to other antihypertensives, such as calcium channel 
blockers (CCBs), may be beneficial [21], but there is very little 
evidence emerging from direct comparisons between these two 
drug classes [11, 14, 22–24], limiting the usefulness of avail-
able studies in clinical practice.
The aim of this population-based Italian retrospective 
cohort study was to investigate whether ACEI/ARB use 
prior to hospitalisation increases or decreases the risk of 
death in a population of over 40,000 patients after they were 
hospitalised with a diagnosis of COVID-19, identified from 
a catchment population of 15.2 million persons in the largest 
study to date.
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2  Methods
A large-scale, retrospective cohort study was conducted in 
the Lombardy and Veneto regions and the Reggio Emilia 
Local Health Unit, covering an underlying population of 
15.2 million persons (25% of the Italian population) overall. 
The protocol was registered in the ENCePP EU-PAS register 
(EUPAS34541).
2.1  Data Source
Italy has a National Health System (NHS) that provides uni-
versal care. Healthcare services provided are collected using 
claims databases that have been widely used for clinical and 
pharmacoepidemiological research [25]. The data used in 
this study were recorded through routine data collection, 
using national data collection systems that were in place 
prior to the start of the study. The following claims data-
bases were used: hospital admissions, pharmacy claims and 
copayment exemptions. Pharmacy claims databases were 
updated as of 31 December 2019, 30 November 2019 and 
29 February 2020 in Lombardy, Veneto and Reggio Emilia, 
respectively. All claims databases date back over 10 years. 
Hospital admissions in the 10 years preceding COVID-19 
hospitalisations, as well as pharmacy claims in the past year, 
were extracted and used to adjust for confounding. Diagno-
ses were recorded using the International Classification of 
Diseases, Clinical Modification, 9th Revision (ICD-CM-9). 
Pharmacy claims in the last available 3 months prior to 
COVID-19-related hospitalisation were used to assess anti-
hypertensive exposure. Drug data were recorded using the 
Anatomical Therapeutic Chemical (ATC) classification 
system and the National Drug Code (NDC). Copayment 
exemption databases were used as an additional source to 
identify diseases that exempt patients from healthcare copay. 
Using unique anonymised patient identifiers, claims data-
bases were all linked locally to the COVID-19 surveillance 
database available in each catchment area. This registry con-
tains information (e.g. hospitalisation date, intensive care 
unit [ICU] admission, death) on patients testing positive for 
SARS-CoV-2 RNA by polymerase chain reaction (PCR) on 
nasopharyngeal/throat swabs. This database has been used 
to identify the study population and outcome, and is updated 
up to 21 April 2020 for Lombardy, and 31 March 2020 for 
Veneto and Reggio Emilia.
An R-based tool for distributed analyses developed by 
the Italian National Institute of Health (The ShinISS) was 
employed by each centre to locally elaborate COVID-19 
patient data using a common data model, sharing only 
a fully anonymised dataset for central analysis, in com-
pliance with EU General Data Protection Regulation 
regulations.
2.2  Study Population
All patients aged ≥ 18 years with SARS-CoV-2 infection 
who were hospitalised from 21 February (date of the first 
confirmed Italian COVID-19 patient hospitalisation) to 21 
April 2020 were identified in the three centres, from the 
local COVID-19 registry. Admission date was considered 
the index date (ID). Included patients were followed-up until 
death (occurring in any setting) or end of the observation 
period, whichever came first.
2.3  Exposure Definition
Exposure of interest was any antihypertensive drug, 
grouped, using pharmacy claims, into the following mutu-
ally exclusive categories: (1) ACEI as monotherapy or fixed 
combination with other antihypertensive drugs, except for 
ARBs and CCBs; (2) ACEIs + CCBs as fixed or non-fixed 
combination; (3) ARBs as monotherapy or fixed combina-
tions with other antihypertensive drugs, except for ACEIs 
and CCBs; (4) ARBs + CCBs as fixed or non-fixed com-
binations; (5) CCBs as monotherapy or fixed combination 
with other antihypertensives, except for ACEIs or ARBs; 
(6) other antihypertensive drugs, including α2-adrenergic 
receptor agonists, β-blockers and diuretics; and (7) non-use 
of any antihypertensive drug (Online Resource 2). A patient 
was considered exposed to each of the above-mentioned 
categories if they had at least one pharmacy claim within 
3 months prior to the ID. The ACEI, ARB or CCB catego-
ries also included a non-fixed combination with drugs from 
other antihypertensive categories.
2.4  Outcomes
The study outcome was all-cause mortality occurring in or 
out of hospital, as reported in the COVID-19 registry.
2.5  Potential Confounders
In addition to sex, age and catchment area, the following 
potential confounders were identified: number of hospitalisa-
tions in the last 2 years and drug dispensing in the last year; 
Charlson index (Online Resource 3); cardiocerebrovascular 
diseases, as well as other acute and chronic diseases; prior 
use of several chronically used drugs and recent use of corti-
costeroids, nonsteroidal anti-inflammatory drugs (NSAIDs), 
and chloroquine/hydroxychloroquine. Information on dis-
eases was extracted from copayment exemption and hospital 
discharge databases within the last 10 years of data avail-
ability (Online Resource 4). Prior and recent drug use was 
assessed using pharmacy claims within the last available 
year and 3 months, respectively (Online Resource 5).
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2.6  Statistical Analysis
Categorical and continuous variables were described using 
frequencies with percentages and medians with interquar-
tile ranges (IQRs), respectively. Mortality risk following 
COVID-19-related hospitalisation was estimated as hazard 
ratios (HRs) along with 95% confidence intervals (CIs), using 
a mixed-effect Cox proportional hazard model, comparing 
ACEIs, ARBs, and other antihypertensives versus CCBs. In 
an additional analysis, risk was estimated considering non-use 
of any antihypertensive as the reference category. We modelled 
catchment area as a random effect. Potential confounders were 
included in the multivariable model using a stepwise Akaike 
information criterion (AIC) method. Proportional hazard 
assumptions were verified on the basis of Schoenfeld residu-
als, and significance was set at a p value < 0.05. All statistical 
analyses were performed using STATA version 16 (StataCorp 
LLC, College Station, TX, USA) and R version 3.6 (The R 
Foundation for Statistical Computing, Vienna, Austria).
2.7  Subgroup and Sensitivity Analyses
First, we estimated mortality risk using a propensity-score 
(PS) matched (1:1) analysis (Online Resources 6 and 7). The 
standardised differences (SDs) between the exposure groups 
for each covariate were estimated (Online Resource 8). The 
nearest-neighbour matching algorithm was used (calliper 
width 0.05 of the standard deviation of the logit score). Sec-
ond, to control for potential confounding effects of diuretics 
and other antihypertensives from the ACEI, ARB and CCB 
categories, we removed those patients receiving non-fixed 
combinations of other antihypertensives. Third, we assessed 
risk estimates only among incident users of antihypertensives 
(i.e. treatment started within the last 3 months prior to the ID, 
with no use within 9 months prior). We also explored mor-
tality risk, stratified by any of the diseases listed among the 
approved treatment indications (hypertension, heart failure, 
acute myocardial infarction and diabetes mellitus as a proxy of 
diabetic nephropathy) and cumulative antihypertensive expo-
sure in the last year (categorised by tertile of the total number 
of defined daily doses (DDDs), with the first tertile being the 
lowest cumulative exposure and the third tertile being the high-
est). The number of DDDs was calculated as the dose of drug 
dispensed multiplied by the quantity dispensed, and dividing 
this product by the DDD for that drug (obtained from www.
whocc .no/atc_ddd_index /). Mortality risk was also estimated 
considering only deaths occurring during hospitalisation. As 
different management of COVID-19 patients and pressure on 
healthcare system in various regions may affect mortality risk, 
we stratified analyses by catchment area. Finally, we explored 
the risk in different calendar periods to account for the centre-
specific heterogeneous length of follow-up and changes in 
COVID-19 management over time.
3  Results
Overall, 42,926 hospitalised COVID-19 patients were 
included in the study (Table 1), with Lombardy accounting 
for 90.2% of these patients (Online Resource 9). Patients’ 
median age was 69 years (IQR 57–79), with a male-to-
female ratio of 1.67. The proportion of COVID-19 patients 
admitted to the ICU, including antihypertensive users and 
non-users, during the hospital stay ranged from 7.6% to 
18.2% in the three catchment areas. In total, 11,205 (26.1%) 
of all patients died over a median follow-up of 24 days (IQR 
10–35) (Table 2). The total number of patients who were 
still hospitalised was 8638 (20.1%), while 22,828 (53.2%) 
were discharged.
Almost 50% of patients had at least one antihypertensive 
drug claim within 3 months prior to the ID. ARB, ACEI 
and CCB users accounted for 11.3%, 10.9% and 5.1% of 
total patients, respectively. The median age of antihyper-
tensive users was 75 years, which was comparable across 
classes, and was much higher than non-users (61 years; IQR 
51–73) (Table 1). Most antihypertensive users were male. 
CCB and other antihypertensive users more commonly had 
two or more hospitalisations (21–26%) prior to the ID, and 
a Charlson index ≥ 3 (13.7–17.3%), compared with ACEI/
ARB users. A very high proportion of cardiovascular dis-
eases and drugs among antihypertensive drug users was 
observed. Categories of other antihypertensives had the most 
severe pattern of comorbidities. Overall, burden of disease 
and prior use of other drugs was much higher among anti-
hypertensive users than non-users.
In univariate analyses, advanced age was the strongest 
predictor of death (Table 2). Male sex, Charlson comorbidity 
index ≥ 1, and most diseases, especially cardiovascular and 
neurodegenerative diseases (and related medications), were 
strongly associated with an increased risk of death. Over-
all, during the follow-up, the proportion of deaths among 
antihypertensive users ranged from 31.7 to 40.2% versus 
17.1% among non-users (Table 3). In comparison with 
CCBs, unadjusted analyses showed a statistically signifi-
cant protective effect for ACEIs and ARBs (also as a fixed-
combination with CCB), while an increased risk for other 
antihypertensive drugs was reported. These statistically sig-
nificant effects disappeared after adjusting for potential con-
founders for ACEI users (HR 0.97, 95% CI 0.89–1.06), ARB 
users (HR 0.98, 95% CI 0.89–1.06), ACEI + CCB users (HR 
0.97, 95% CI 0.90–1.05), ARB + CCB users (HR 1.02, 95% 
CI 0.94–1.11), and other antihypertensives (HR 1.05, 95% 
CI 0.96–1.14). In comparison with non-use, a statistically 
significant 2/2.5-fold increased mortality risk was seen for 
ACEI, ARB and CCB use in unadjusted analysis. In multi-
variable analysis, this effect almost completely disappeared, 
although risk estimates were still marginally significant 
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ACEI + CCB 





N (%)a 42,926 21,974 (51.2) 4859 (11.3) 4663 (10.9) 2178 (5.1) 2318 (5.4) 2609 (6.1) 4068 (9.5)
Age, years 
[median (IQR)]
69 (57–79) 61 (51–73) 73 (65–81) 75 (65–82) 77 (68–83) 74 (67–81) 75 (66–81) 77 (68–84)
Age, years [n (%)]
 18–49 5561 (13.0) 5031 (22.9) 126 (2.6) 114 (2.4) 52 (2.4) 54 (2.3) 70 (2.7) 108 (2.7)
 50–59 7172 (16.7) 5178 (23.6) 531 (10.9) 424 (9.1) 178 (8.2) 238 (10.3) 254 (9.7) 342 (8.4)
 60–69 8754 (20.4) 4621 (21.0) 1118 (23.0) 894 (19.2) 386 (17.7) 463 (20.0) 548 (21.0) 665 (16.3)
 70–79 10,953 (25.5) 3912 (17.8) 1626 (33.5) 1611 (34.5) 675 (31.0) 840 (36.2) 922 (35.3) 1269 (31.2)
 80–89 8880 (20.7) 2653 (12.1) 1285 (26.4) 1392 (29.9) 753 (34.6) 653 (28.2) 703 (26.9) 1380 (33.9)
 ≥ 90 1606 (3.7) 579 (2.6) 173 (3.6) 228 (4.9) 134 (6.2) 70 (3.0) 112 (4.3) 304 (7.5)
Sex [n (%)]





24 (10–35) 26 (13–36) 23 (9–35) 20 (8–34) 20 (7–33) 21 (8–34) 21 (8–34) 18 (7–33)
Admitted to ICU 
[n (%)]
4392 (10.2) 2424 (11.0) 502 (10.3) 411 (8.8) 181 (8.3) 279 (12.0) 307 (11.8) 261 (6.4)
No. of hospi-
talisations 
within the last 
12 months 
[n (%)]
 0 31,458 (73.3) 17,685 (80.5) 3530 (72.6) 3202 (68.7) 1311 (60.2) 1608 (69.4) 1776 (68.1) 2185 (53.7)
 1 6452 (15.0) 2722 (12.4) 776 (16.0) 819 (17.6) 409 (18.8) 392 (16.9) 456 (17.5) 826 (20.3)
 2 2600 (6.1) 868 (4.0) 338 (7.0) 328 (7.0) 201 (9.2) 171 (7.4) 211 (8.1) 460 (11.3)
 ≥ 3 2416 (5.6) 699 (3.2) 215 (4.4) 314 (6.7) 257 (11.8) 147 (6.3) 166 (6.4) 597 (14.7)
Charlson index 
[n (%)]
 0 29,775 (69.4) 17,979 (81.8) 3225 (66.4) 2716 (58.2) 1061 (48.7) 1416 (61.1) 1534 (58.8) 1718 (42.2)
 1–2 10,575 (24.6) 3463 (15.8) 1373 (28.3) 1580 (33.9) 819 (37.6) 724 (31.2) 861 (33.0) 1645 (40.4)
 ≥ 3 2576 (6.0) 532 (2.4) 261 (5.4) 367 (7.9) 298 (13.7) 178 (7.7) 214 (8.2) 705 (17.3)
No. of pharmacy 
claims [median 
(IQR)]
 Within the last 
12 months
15 (3–36) 3 (0–13) 27 (14–44) 30 (17–49) 36 (20–56) 36 (22–56) 34 (20–53) 37 (21–59)
 Within the last 
3 months
3 (0–9) 0 (0–3) 7 (3–11) 7 (4–12) 8 (5–14) 9 (5–14) 9 (5–13) 9 (5–14)
Drug use 
within the last 
12 months 
[n (%)]
 Anticoagulants 6743 (15.7) 1708 (7.8) 937 (19.3) 1039 (22.3) 523 (24) 481 (20.8) 529 (20.3) 1468 (36.1)
 Platelet aggrega-
tion inhibitors
9025 (21.0) 1649 (7.5) 1429 (29.4) 1659 (35.6) 826 (37.9) 851 (36.7) 964 (36.9) 1533 (37.7)
 Lipid-modifying 
agents




1924 (4.5) 345 (1.6) 329 (6.8) 316 (6.8) 148 (6.8) 177 (7.6) 155 (5.9) 433 (10.6)
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ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, CCB calcium channel blocker, COPD chronic obstructive pul-
monary disease, anti-HT antihypertensive drugs (includes α2-adrenergic agonist, diuretics and β-blockers), ICU intensive care unit, IQR inter-
quartile range, HIV human immunodeficiency virus, NSAIDs non-steroidal anti-inflammatory drugs
a We removed 257 patients from the analysis who were concomitantly treated with ARBs and ACEIs (± CCBs or other antihypertensive drugs). 
The mortality rate of these patients was comparable with that of all other antihypertensive categories
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 Drugs for peptic 
ulcer





6356 (14.8) 2337 (10.6) 927 (19.1) 781 (16.7) 467 (21.4) 464 (20.0) 411 (15.8) 919 (22.6)
 Antibiotics 17,513 (40.8) 7372 (33.5) 2280 (46.9) 2177 (46.7) 1119 (51.4) 1084 (46.8) 1172 (44.9) 2190 (53.8)
 Anti-HIV drugs 300 (0.7) 136 (0.6) 28 (0.6) 28 (0.6) 24 (1.1) 9 (0.4) 21 (0.8) 48 (1.2)
 Anti-Parkinson 
drugs
754 (1.8) 273 (1.2) 88 (1.8) 112 (2.4) 55 (2.5) 38 (1.6) 62 (2.4) 121 (3.0)
 Antiepileptics 2936 (6.8) 1056 (4.8) 336 (6.9) 401 (8.6) 215 (9.9) 183 (7.9) 209 (8.0) 508 (12.5)
 Antipsychotics 1737 (4.0) 768 (3.5) 172 (3.5) 217 (4.7) 98 (4.5) 76 (3.3) 94 (3.6) 304 (7.5)













222 (0.5) 69 (0.3) 42 (0.9) 35 (0.8) 13 (0.6) 14 (0.6) 16 (0.6) 28 (0.7)
 Immunosup-
pressants





4436 (10.3) 710 (3.2) 632 (13) 903 (19.4) 378 (17.4) 343 (14.8) 432 (16.6) 994 (24.4)
 Atrial fibrilla-
tion
2899 (6.8) 550 (2.5) 379 (7.8) 485 (10.4) 221 (10.1) 188 (8.1) 229 (8.8) 819 (20.1)
 Heart failure 2684 (6.3) 447 (2.0) 335 (6.9) 498 (10.7) 229 (10.5) 136 (5.9) 183 (7.0) 831 (20.4)
 Hypertension 5610 (13.1) 1097 (5.0) 897 (18.5) 878 (18.8) 552 (25.3) 535 (23.1) 626 (24.0) 960 (23.6)
 Cerebrovascular 
diseases
3441 (8.0) 1041 (4.7) 387 (8.0) 474 (10.2) 305 (14.0) 247 (10.7) 330 (12.6) 623 (15.3)
 Diabetes mel-
litus
7710 (18.0) 1946 (8.9) 1234 (25.4) 1206 (25.9) 608 (27.9) 718 (31.0) 818 (31.4) 1082 (26.6)
 Liver disease 701 (1.6) 239 (1.1) 75 (1.5) 81 (1.7) 55 (2.5) 41 (1.8) 37 (1.4) 170 (4.2)
 Dementia 1014 (2.4) 444 (2.0) 90 (1.9) 126 (2.7) 70 (3.2) 46 (2.0) 50 (1.9) 183 (4.5)
 Pneumonia and 
influenza
2737 (6.4) 885 (4.0) 274 (5.6) 353 (7.6) 242 (11.1) 134 (5.8) 197 (7.6) 634 (15.6)
 Renal failure 1046 (2.4) 255 (1.2) 97 (2.0) 106 (2.3) 158 (7.3) 74 (3.2) 74 (2.8) 270 (6.6)
 COPD 1521 (3.5) 389 (1.8) 178 (3.7) 210 (4.5) 162 (7.4) 108 (4.7) 87 (3.3) 376 (9.2)
 Cancer 6446 (15.0) 2520 (11.5) 780 (16.1) 875 (18.8) 479 (22.0) 409 (17.6) 455 (17.4) 883 (21.7)
 Rheumatic 
diseases
375 (0.9) 107 (0.5) 48 (1.0) 51 (1.1) 42 (1.9) 23 (1.0) 18 (0.7) 81 (2.0)
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Table 2  Risk factors of all-cause mortality in COVID-19 hospitalised patients, at univariate analysis
Covariate No. of COVID-19 patients 
[n = 42,926]
No. of deaths (%) 
[n = 11,205 (26.1)]
Unadjusted HR (95% CI)
Centre
 Lombardy 38,715 10,569 (27.3) Ref.
 Reggio Emilia 982 197 (20.1) 0.98 (0.86–1.13)
 Veneto 3229 439 (13.6) 0.66 (0.60–0.72)
Age, years
 18–49 5561 141 (2.5) Ref.
 50–59 7172 451 (6.3) 2.49 (2.06–3.01)
 60–69 8754 1484 (17.0) 7.04 (5.92–8.37)
 70–79 10,953 3867 (35.3) 16.8 (14.2–19.8)
 80–89 8880 4343 (48.9) 27.6 (23.3–32.6)
 ≥ 90 1606 919 (57.2) 37.5 (31.4–44.8)
Sex
 Male 26,873 7662 (28.5) Ref.
 Female 16,053 3543 (22.1) 0.77 (0.74–0.80)
No. of hospitalisations within the last 12 months
 0 31,458 7181 (22.8) Ref.
 1 6452 2013 (31.2) 1.45 (1.38–1.52)
 2 2600 1015 (39.0) 1.93 (1.80–2.06)
 ≥ 3 2416 996 (41.2) 2.05 (1.92–2.19)
Charlson index
 0 29,775 5805 (19.5) Ref.
 1–2 10,575 4018 (38.0) 2.24 (2.15–2.33)
 ≥ 3 2576 1382 (53.6) 3.65 (3.44–3.87)
Drug use within the last 12 months vs. non-use
 Anticoagulants 6743 2632 (39.0) 1.84 (1.76–1.92)
 Platelet aggregation inhibitors 9025 3775 (41.8) 2.22 (2.14–2.31)
 Lipid-modifying agents 12,550 4516 (36.0) 1.78 (1.72–1.85)
 Antiarrhythmics, class I and III 1924 800 (41.6) 1.82 (1.70–1.96)
 Drugs for peptic ulcer 16,192 5738 (35.4) 1.91 (1.84–1.98)
 Drugs for obstructive airway diseases 6356 2052 (32.3) 1.33 (1.27–1.40)
 Antibiotics 17,513 5066 (28.9) 1.22 (1.17–1.27)
 Anti-HIV drugs 300 95 (31.7) 1.22 (1.00–1.50)
 Anti-Parkinson drugs 754 357 (47.3) 2.20 (1.98–2.44)
 Antiepileptics 2936 1063 (36.2) 1.54 (1.45–1.64)
 Antipsychotics 1737 750 (43.2) 2.01 (1.86–2.16)
 Antidepressants 5339 1935 (36.2) 1.62 (1.54–1.70)
Drug use within the last 3 months vs. non-use
 NSAIDs 2680 781 (29.1) 1.15 (1.07–1.23)
 Corticosteroids for systemic use 2358 847 (35.9) 1.51 (1.41–1.62)
 Chloroquine/hydroxychloroquine 222 78 (35.1) 1.44 (1.16–1.80)
 Immunosuppressants 695 183 (26.3) 1.01 (0.87–1.16)
Comorbidities vs. absence of the disease
 Ischaemic heart disease 4436 2013 (45.4) 2.22 (2.12–2.33)
 Atrial fibrillation 2899 1323 (45.6) 2.19 (2.07–2.32)
 Heart failure 2684 1416 (52.8) 2.74 (2.59–2.90)
 Hypertension 5610 2396 (42.7) 2.11 (2.02–2.21)
 Cerebrovascular diseases 3441 1554 (45.2) 2.23 (2.12–2.36)
 Diabetes mellitus 7710 3041 (39.4) 1.92 (1.84–2.00)
 Pneumonia and influenza 2737 1313 (48.0) 2.34 (2.21–2.48))
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for users of ACEIs (HR 1.10, 95% CI 1.03–1.17), ARBs 
(HR 1.12, 95% CI 1.05–1.20) and CCBs (HR 1.11, 95% CI 
1.03–1.21). Among hypertensive patients only, this effect 
disappeared (Fig. 1). The main finding that there is no sig-
nificantly increased risk of death with ACEI/ARB treatment 
compared with CCB treatment was confirmed in other sen-
sitivity analyses, including the PS-matched analysis, which 
included 2031 ARB users (41.9% of all ARB users in the 
cohort) matched to 2031 CCB users (93.2% of all CCB users 
in the cohort), and 2094 ACEI users (45.1% of all ACEI 
users in the cohort) matched to 2094 CCB users (96.1% of 
all CCB users in the cohort) (Fig. 1). Results for in-hospital 
death as the outcome (n = 9878) were very similar to death 
defined for the main analysis, with no significant risk for 
ARBs or ACEIs compared with CCBs (HR 0.99, 95% CI 
0.90–1.07; and HR 0.98, 95% CI 0.90–1.07, respectively). 
HR hazard ratio, CI confidence interval, COPD chronic obstructive pulmonary disease, HIV human immunodeficiency virus, NSAID non-steroi-
dal anti-inflammatory drug, Ref. reference group
Table 2  (continued)
Covariate No. of COVID-19 patients 
[n = 42,926]
No. of deaths (%) 
[n = 11,205 (26.1)]
Unadjusted HR (95% CI)
 Liver disease 701 286 (40.8) 1.73 (1.54–1.94)
 Dementia 1014 535 (52.8) 2.76 (2.53–3.01)
 Renal failure 1046 498 (47.6) 2.24 (2.05–2.45)
 COPD 1521 699 (46.0) 2.10 (1.94–2.27)
 Cancer 6446 2344 (36.4) 1.63 (1.56–1.70)
 Rheumatic diseases 375 159 (42.4) 1.96 (1.67–2.29)
Table 3  Unadjusted and adjusted hazard ratio of all-cause mortality in hospitalised COVID-19 patients in relation to antihypertensive exposure 
within the last 3 months of observation
ACEIs ACE inhibitors, ARBs angiotensin receptor blockers, CCBs calcium channel blockers, CI confidence interval, COPD chronic obstructive 
pulmonary disease, anti-HT antihypertensive drugs (α2-adrenergic agonist, diuretics, and β-blockers), HR hazard ratio, HIV human immunodefi-
ciency virus, NSAIDs non-steroidal anti-inflammatory drugs
a Cox proportional regression model (stepwise forward based on Akaike’s information criterion) adjusted for the following eligible variables: 
centre, age, sex, Charlson index, number of drug dispensings, drugs for peptic ulcer, anticoagulants, antiplatelet drugs, lipid-modifying agents, 
antiarrhythmic drugs, drugs for obstructive airway diseases, antibiotics, anti-HIV drugs, anti-Parkinson drugs, antiepileptic drugs, antipsychot-
ics, antidepressants, NSAIDS, corticosteroids, chloroquine/hydroxychloroquine, immunosuppressants, pneumonia and influenza, ischaemic heart 
disease, atrial fibrillation, heart failure, hypertension, cerebrovascular diseases, diabetes mellitus, liver disease, dementia, renal failure, COPD, 
cancer, and rheumatic diseases
b ARBs as monotherapy or fixed combination with other HT drugs, except for ACEIs and CCBs or ARBs + CCBs as fixed combination
c ACEIs as monotherapy or fixed combination with other HT drugs, except for ARBs and CCBs or ACEIs + CCBs as fixed combination
d ARBs + CCBs as fixed combination
e ACEIs + CCBs as fixed combination
No of deaths (% of 
total users)
No. of total users Unadjusted HR (95% CI) Adjusted  HRa (95% CI)
ARBs 1540 (31.7) 4859 0.79 (0.72–0.86) 0.98 (0.89–1.06)
ACEIs 1606 (34.4) 4663 0.89 (0.81–0.96) 0.97 (0.89–1.06)
Other anti-HT drugs 1634 (40.2) 4068 1.08 (1.00–1.18) 1.05 (0.96–1.14)
ARBs + CCBsb 2399 (33.4) 7177 0.84 (0.77–0.91) 1.02 (0.94–1.11)
ACEIs + CCBsc 2496 (34.3) 7272 0.88 (0.82–0.96) 0.97 (0.90–1.05)
CCBs 822 (37.7) 2178 Reference category Reference category
ARBs 1540 (31.7) 4859 1.99 (1.87–2.11) 1.12 (1.05–1.20)
ACEIs 1606 (34.4) 4663 2.24 (2.11–2.37) 1.10 (1.03–1.17)
CCBs 822 (37.7) 2178 2.52 (2.34–2.72) 1.11 (1.03–1.21)
ARBs + CCBsd 859 (37.1) 2318 2.40 (2.23–2.58) 1.29 (1.19–1.40)
ACEIs + CCBse 890 (34.1) 2609 2.21 (2.05–2.37) 1.13 (1.04–1.22)
Other anti-HT drugs 1634 (40.2) 4068 2.73 (2.58–2.90) 1.17 (1.09–1.25)
Non-use of any anti-HT drug 3766 (17.1) 21,974 Reference category Reference category
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Findings regarding in-hospital death were also similar to 
the main analysis for ARBs and ACEIs in comparison with 
the non-use of antihypertensive drugs (HR 1.13, 95% CI 
1.06–1.21; and HR 1.12, 95% 1.04–1.20, respectively). 
There was no trend in mortality risk on increasing cumula-
tive exposure in comparison with CCBs, either for ACEIs 
or ARBs. Interestingly, there was a non-significant trend for 
calendar time, where, both for ACEIs and ARBs, there was 
a non-significant higher risk of death after 11 April 2020. 
Stratification by catchment area resulted in findings that 
were likely underpowered for Veneto and Reggio Emilia, 
although these results are also in line with the main analysis.
Fig. 1  Sensitivity and subgroup analyses of all-cause mortality risk 
in hospitalised COVID-19 patients in association with ACEIs/ARBs 
vs. CCBs (or non-use). AMI acute myocardial infarction, ACEIs 
angiotensin-converting enzyme inhibitors, ARBs angiotensin recep-
tor blocker, CCBs calcium channel blockers, CI confidence interval, 
AH antihypertensive drugs (α2-adrenergic agonist, diuretics, and 
β-blockers, NSAIDs non-steroidal anti-inflammatory drugs, COPD 
chronic obstructive pulmonary disease, LO Lombardy region, HIV 
human immunodeficiency virus, HR hazard ratio, RE Reggio Emilia 
LHU, VE Veneto region, DDDs defined daily doses. ^Cox propor-
tional regression model (stepwise forward based on Akaike’s infor-
mation criterion) adjusted for the following eligible variables: centre, 
age, sex, Charlson index, number of drug dispensings, drugs for pep-
tic ulcer, anticoagulants, antiplatelet drugs, lipid-modifying agents, 
antiarrhythmics, drugs for obstructive airway diseases, antibiotics, 
anti-HIV drugs, anti-Parkinson drugs, antiepileptics, antipsychotics, 
antidepressants, NSAIDS, corticosteroids, chloroquine/hydroxychlo-
roquine, immunosuppressants, pneumonia and influenza, ischaemic 
heart disease, atrial fibrillation, heart failure, hypertension, cerebro-
vascular diseases, diabetes mellitus, liver disease, dementia, renal 
failure, COPD, cancer, and rheumatic diseases. *Propensity-score 
matched Cox regression model. **ARB: 1° tertile: upper tertile of 
number of DDDs in the last year: < 224; 2° tertile: intermediate ter-
tile: 224–419; 3° tertile: low tertile: ≥ 420; ACEI: 1° tertile: upper ter-
tile < 280; 2° tertile: intermediate tertile: 280–615; 3° tertile: low ter-
tile: ≥ 616. ***Only the Lombardy region. ****Cox regression model 
adjusted by propensity score
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4  Discussion
The present study is the largest to date to investigate the 
safety of ACEIs and ARBs in persons with COVID-19. The 
main finding of this study was that prior exposure to ACEIs/
ARBs among new users of these drugs neither worsened nor 
improved the prognosis of hospitalised COVID-19 patients 
in terms of all-cause mortality compared with CCBs. The 
sample size of the study allowed us to conduct several sup-
porting and sensitivity analyses. We observed no increased 
risk of death among ACEI or ARB users having the highest 
drug cumulative exposure (upper tertile of DDDs) within 
1 year prior to the ID, compared with CCB use. This finding 
was confirmed in several supporting and sensitivity analyses, 
using the PS matching approach or changing exposure and 
outcome definitions.
When considering non-use as a comparator, the 2/2.5-
fold increased risk of death with all antihypertensive drugs 
in unadjusted analyses almost completely disappeared after 
controlling for confounders, yielding a marginally signifi-
cant 10–15% increased mortality risk, likely attributable to 
residual confounding by indication. Accordingly, in hyper-
tensive patients specifically, no statistically significant dif-
ference in risk for ACEI/ARB use versus non-use of antihy-
pertensives was observed. This finding is in line with three 
small Chinese retrospective studies demonstrating that in-
hospital exposure to ACEIs/ARBs in hypertensive COVID-
19 patients was not associated with increased mortality [14, 
24]. Larger studies have also shown a lack of association 
between these drug classes and severe COVID-19, as meas-
ured by outcomes such as intensive care or death [11, 26].
The studies reporting a potentially protective effect were 
either not published in peer-reviewed scientific journals [14, 
27], were not full research papers but letters with limited 
detail [28], or were retracted [29]. While previous observa-
tional studies provided preliminary evidence that there is no 
additional risk of mortality with RAAS inhibitors compared 
with other antihypertensive drugs in COVID-19 patients, 
estimates from this large-scale study, based on extensive 
adjustment for potential confounders and numerous sensitiv-
ity analyses, confirm that there is no increase in risk. In addi-
tion, we showed that there is no protective effect of ACEIs/
ARBs, as previously reported in a meta-analysis of obser-
vational studies [18] that were mainly conducted through 
retrospective assessment of small cohorts of hospitalised 
patients with COVID-19. The present study is based on a 
much larger study population, more extensive adjustment 
for confounding and a larger battery of sensitivity analyses.
This study has several strengths. First, we performed the 
study using a large multiple database network with quasi 
real-time data access for over 40,000 COVID-19 hospital-
ised patients from three regions, each of which was heavily 
affected by SARS-CoV-2 infection. The data used in the 
present study were collected while the pandemic was at its 
peak, increasing the significance of our findings. While an 
observational study set in Lombardy has already been pub-
lished [11], the present study has over 1 month of additional 
data, with a population size that is approximately seven 
times as large. The estimated overlap between our hospital-
ised population and that of Mancia et al. is approximately 
6%, with the total number of ACEI/ARB users being around 
720 [11]. Moreover, the study design by Mancia et al. was 
not intended to evaluate how RAAS inhibitors could affect 
the prognosis among persons with COVID-19, and there-
fore may not be very informative in this regard. Second, the 
use of the COVID-19 patient registry, which is maintained 
by the Italian NHS and updated daily, leverages accurately 
collected data on patients testing positive for SARS-CoV-2 
RNA by PCR on nasopharyngeal/throat swabs. Third, this is 
the largest cohort of COVID-19 patients, at least in Europe, 
that has been analysed at a population-based level to date. 
This large sample size allowed us to perform a number of 
sensitivity/subgroup analyses, thus increasing the robust-
ness of study findings. A variety of approaches were used to 
control for confounding, including stratification by comor-
bidity and cumulative exposure, as well as the use of PSs. 
We were able to adjust for a very large number of potential 
confounders by leveraging Italian NHS claims databases that 
have been used widely, by linking them at the individual 
patient level to the COVID-19 surveillance registry. Regard-
ing the exposure, in the present study we have distinguished 
between ACEI and ARB use as monotherapy or combination 
therapy, which has not always been done in previous studies 
[14, 23, 24, 30]. We selected a comparator, CCB use, which 
is a therapeutic alternative to ACEI/ARB use, making our 
findings relevant to decision making in clinical practice. This 
has also not always been done in previous studies [14, 23, 
24, 30]. Finally, to our knowledge, the present study is the 
only study that has investigated the dose–effect response on 
the risks associated with ACEI/ARB use. Dose–effect analy-
ses are essential to demonstrate the biological plausibility of 
a hypothesised drug-related risk. A different outcome defini-
tion was also applied, i.e. in-hospital mortality, in addition 
to the primary outcome definition, i.e. all-cause mortality in 
any setting. This not only further confirms the main findings 
but also shows the lack of competing risks.
Nevertheless, some limitations warrant caution. We had 
access to pharmacy claims of COVID-19 patients up to 29 
February 2020, 31 December 2019 and 30 November 2019 
in Reggio Emilia, Lombardy and Veneto, respectively. As 
such, we may have misclassified exposure, especially in 
Lombardy and Veneto, if antihypertensive users withdrew/
switched therapies due to concerns about SARS-COV-2 
infection in the period immediately preceding COVID-19 
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hospitalisation. However, in the trimester prior to COVID-
19 hospitalisation in Reggio Emilia, only 1.5% and 1.4% 
of ACEI and ARB users, respectively, switched to CCBs. 
We have no reason to believe that this trend was different in 
the other two Northern Italian catchment areas considered. 
COVID-19 patients with the lowest cumulative exposure to 
antihypertensive drugs in the past year (as a proxy of low 
adherence), who may be more likely to withdraw therapy, 
were not associated with higher death risk, compared with 
CCBs. We did not have information on risk factors for death 
in COVID-19 patients such as obesity and smoking; how-
ever, we adjusted the analysis for comorbidities strictly cor-
related to these variables (e.g. diabetes mellitus and chronic 
obstructive pulmonary disease), thus potentially account-
ing for their confounding effect. We explored the exposure 
status only in an outpatient setting, and we do not know if 
antihypertensive drugs were continued during hospital stay. 
Finally, some comorbidities that are not likely to be the 
cause of hospitalisation, especially chronic conditions such 
as hypertension and diabetes, may be underestimated as they 
were mainly identified from hospital discharge diagnoses. 
Another limitation is that there may be potential bias in our 
cohort of hospitalised patients as the criteria for hospital 
admission are not defined and may depend on several fac-
tors, including severity, availability of hospital beds, etc., 
that are likely to vary from hospital to hospital. Neverthe-
less, a case–control study conducted in Italy has shown that 
there is no difference between ACEI or ARB use and the risk 
of hospitalisation among COVID-19 patients [11].
5  Conclusion
This large Italian population-based cohort study demon-
strated that prior exposure to ACEIs and ARBs is not asso-
ciated with either an increased or decreased risk of all-cause 
mortality in hospitalised COVID-19, in comparison with 
CCBs. This finding strengthens recommendations from 
international regulatory drug agencies and scientific socie-
ties about not withdrawing ACEI/ARB therapies or switch-
ing to other antihypertensive drugs for the prevention of 
COVID-19-related death. Furthermore, this study shows that 
real-world evidence generation during healthcare emergen-
cies may rapidly confirm or refute hypotheses derived from 
in vitro studies.
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